MOSUNETUZUMAB
UNII LDJ89SS0YG

Substance Identification & Data

This profile provides standardized clinical and technical data for Mosunetuzumab, uniquely identified by the FDA Unique Ingredient Identifier (UNII) LDJ89SS0YG.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 1905409-39-3 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

LDJ89SS0YG

CAS Registry Number

1905409-39-3

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

MOSUNETUZUMAB

Official standardized name for this substance within the FDA UNII nomenclature system.

Molecular Formula

LDJ89SS0YG

The specific atomic composition represented as a molecular structure string.

NCI Thesaurus

C129691

National Cancer Institute reference terminology for clinical and research data.

INN ID

10621

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

FG-70

Identifier assigned by the United States Adopted Names Council.

Substance Type

MOSUNETUZUMAB

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Mosunetuzumab. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

MOSUNETUZUMAB

Mosunetuzumab-AXGB

Common Names & Synonyms

MOSUNETUZUMAB [USAN]

Mosunetuzumab [MI]

Mosunetuzumab [WHO-DD]

Mosunetuzumab axgb [WHO-DD]

mosunetuzumab [INN]

Brand / Trade Names

LUNSUMIO

Systematic Nomenclature

IMMUNOGLOBULIN G1, HUMANIZED BISPECIFIC, ANTI-(HUMAN CD3 (ANTIGEN))(BTCT4465A .GAMMA.1-CHAIN), DISULFIDE WITH ANTI-(HUMAN CD3 (ANTIGEN)) BTCT4465A .KAPPA.4-CHAIN, ANTI-(HUMAN CD20 (ANTIGEN)) BTCT4465A .GAMMA.3-CHAIN AND ANTI-(HUMAN CD20 (ANTIGEN)) BTCT4465A .KAPPA.1-CHAIN

SYS

IMMUNOGLOBULIN G1-KAPPA ANTI-(HOMO SAPIENS T-CELL SURFACE GLYCOPROTEIN CD3 EPSILON CHAIN (CD3E ANTIGEN)) AND IMMUNOGLOBULIN G1-KAPPA ANTI-(HOMO SAPIENS B-LYMPHOCYTE ANTIGEN CD20) HETERODIMERHUMANIZED MONOCLONAL ANTIBODY BISPECIFIC.GAMMA.1 HEAVY CHAIN ANTI-CD3E (1-449) (HUMANIZED VH (HOMO SAPIENS IGHV1-3*01 (83%) (IGHD)-IGHJ4*01) (8.8.12) (1-119) -HOMO SAPIENS IGHG1*01 (CH3(D16>E(358),L18>M(360) ,T26>S(368),L28>A(370),Y67>V(409))) (120-449)) (222-219')-DISULFIDE WITH KAPPA LIGHT CHAIN ANTI-CD3E (1'-219') (HUMANIZED V-KAPPA (HOMO SAPIENS IGKV4-1*01 (92%) IGKJ1*01) (12.3.8) (1'-112') -HOMO SAPIENS IGKC*01 (113'-219')) AND .GAMMA.1 HEAVY CHAIN ANTI-CD20 (1-452) (HUMANIZED VH (HOMO SAPIENS IGHV3-23*04 (82%) (IGHD)-IGHJ4*01 (93%)) (8.8.15) (1-122) -HOMO SAPIENS IGHG1*03 (CH1(R97>K(219),), CH2(N67>G(302)), CH3(T26>W(371))) (123-452)) (225-213')-DISULFIDE WITH KAPPA LIGHT CHAIN ANTI-CD20 (1'-213') (HUMANIZED V-KAPPA (HOMO SAPIENS IGKV1-39*01 (87%) IGKJ1*01) (5.3.9) (1'-106') -HOMO SAPIENS IGKC*01 (107-213')), HETERODIMER (228-231'':231-234'')-BISDISULFIDE

SYS